Ambalal Sarabhai Enterprises share price
NSE: AMBALALSABSE: 500009Pharmaceuticals & BiotechnologySmall Cap
Last close ₹34.65down ₹1.79 (4.91%)BSE ₹34.60
Share price at the NSE close on 23 Oct 2026. Previous close ₹36.44.
52-week range of BSE trades to 23 Oct 2026
₹23.12Low, 28 Jan 2026₹49.98High, 20 Aug 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹266 Cr2,324th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 19.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 May 2026
- 1.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 9.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 5.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 May 2026
- 0.33
- Volume, NSEVolume. Shares traded on the last trading day.
- 46,405
Results
Standalone, as consolidated accounts are on record for only 8 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 12 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.54 Crdown 64.19%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.03 Crdown 98.86%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 5.5%
Revenue by year
Peak revenue ₹4.04 Cr, year to Mar 2025
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 15 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 13 Aug | Sep 2025Filed 12 Nov | Dec 2025Filed 12 Feb | Mar 2026Filed 21 May | Jun 2026Filed 12 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.17 | 1.73 | 1.64 | 0.79 | 0.00 | 1.52 | 0.54 |
| Net profit | 4.31 | 8.43 | −4.96 | 6.88 | −0.38 | 1.84 | 2.65 | 0.03 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | – | 722.3% | −287.0% | 420.8% | −48.5% | – | 174.6% | 5.5% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹111 Crup 1.91%54.6%
- ElectronicsElectronics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹92 Crup 4.59%45.4%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 61% of 1,107 trading days over the last 5 years.
LowestHighest
Its median14.0Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 15% of 1,948 trading days since Nov 2018.
LowestHighest
Its median2.6Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.20.1
At or below today's level on 23% of 1,222 trading days over the last 5 years.
LowestHighest
Its median32.2Industry median18.7
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −30.8% | +32.4% | −47.7% | 0.0% |
| 3 years | +5.8% | +38.4% | −23.5% | 0.0% |
| 5 years | +6.6% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2023.
Mutual funds holding it
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 1,409 | 0.01% | ₹56,000 |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 664 | 0.01% | ₹26,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Ambalal Sarabhai Enterprises in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 340 | – | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Astonea LabsASTONEALAB | 340 | 75.2 | 5.9 | – | – | – | 12.0% | – | 0.00% |
 Lyka LabsLYKALABS | 293 | – | 3.2 | – | −2.6% | – | −9.2% | −8.0% | 0.00% |
 Astal LaboratoriesASTALLTD | 279 | 28.7 | 0.9 | 19.3 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
 Zenotech LaboratoriesZENOTECH | 246 | – | 2.6 | 61.1 | +4.6% | – | −2.6% | −3.9% | 0.00% |
 BDH IndustriesBDH | 244 | 20.8 | 3.2 | 14.2 | +44.8% | +22.9% | 16.1% | 18.2% | 1.18% |
 Everest OrganicsEVERESTO | 222 | 42.2 | 2.9 | 13.8 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
 Gennex LaboratoriesGENNEX | 211 | 11.5 | 0.9 | 9.1 | +24.1% | +7.3% | 9.0% | 7.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Aug 2026
13 Aug · Submission Of Quarterly Snapshots
5 Aug · Board meeting
Meeting on 12 Aug 2026: quarterly results5 Aug · Legal
Exchange has sought clarification from Ambalal Sarabhai Enterprises Ltd on August 5, 2026 with reference to significant movement in price, in order to ensure that investors have latest ....
Ambalal Sarabhai Enterprises share price by year
Each calendar year to 2025.Ambalal Sarabhai Enterprises share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 28.58 | −46.7% | 57.48 | 26.39 |
| 2024BSE close | 53.58 | +40.9% | 72.49 | 39.92 |
| 2023BSE close | 38.02 | +41.3% | 47.02 | 20.51 |
| 2022BSE close | 26.90 | −20.1% | 45.00 | 25.95 |
| 2021BSE close | 33.65 | +66.2% | 63.80 | 17.40 |
| 2020BSE close | 20.25 | +29.1% | 29.50 | 12.60 |
| 2019BSE close | 15.69 | +18.5% | 18.95 | 9.20 |
| 2018BSE close | 13.24 | +27.8% | 16.47 | 9.51 |
| 2017BSE close | 10.36 | +43.1% | 14.68 | 7.09 |
| 2016BSE close | 7.24 | −6.6% | 10.98 | 4.58 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 36.50 | 36.50 | 34.62 | 34.65 | 35.13 | 46,405 |
| 22 Oct 2026 | 36.10 | 37.00 | 36.10 | 36.44 | 36.58 | 22,737 |
| 21 Oct 2026 | 38.98 | 38.98 | 36.59 | 36.65 | 37.06 | 32,710 |
| 19 Oct 2026 | 38.20 | 39.00 | 37.65 | 38.51 | 38.62 | 50,348 |
| 16 Oct 2026 | 37.80 | 38.35 | 36.51 | 37.79 | 37.42 | 38,651 |
| 15 Oct 2026 | 38.80 | 39.09 | 37.10 | 37.85 | 37.70 | 19,688 |
| 14 Oct 2026 | 38.30 | 39.20 | 38.30 | 38.93 | 38.61 | 24,542 |
| 13 Oct 2026 | 38.75 | 38.94 | 38.30 | 38.42 | 38.63 | 45,122 |
| 12 Oct 2026 | 40.49 | 40.49 | 38.60 | 38.75 | 39.09 | 61,744 |
| 9 Oct 2026 | 41.08 | 41.08 | 39.00 | 40.59 | 40.00 | 53,866 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Ambalal Sarabhai Enterprises Limited
- NSE symbol
- AMBALALSA
- BSE code
- 500009
- ISIN
- INE432A01017
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jun 1981
- Face value
- ₹10
- CIN
- L52100GJ1978PLC003159
- Corporate identity number, the registrar of companies' code for it